One such important clinical trial determined the effect of trastuzumab in combination with various chemotherapies (i.e., anthracycline, cyclophosphamide, doxorubicin and/or epirubicin) for patients with HER2-overexpressing breast cancer [182]. The gene discussed is ERBB2; the disease is breast carcinoma.